Literature DB >> 2897806

Intranasal sufentanil for pre-operative sedation.

M Vercauteren1, E Boeckx, G Hanegreefs, H Noorduin, G Vanden Bussche.   

Abstract

Sufentanil, a short-acting and potent narcotic agent, was studied as a premedicant administered by the nasal route. A total dose of 5 micrograms appeared to be too low, while either 10 or 20 micrograms was very effective in producing sedation. Side effects were minor. There appeared to be no differences between nose drops and spray. In a further study, sufentanil nose drops were compared with saline 0.9% in a double-blind fashion. Sedation of rapid onset but of limited duration was observed in the majority of patients who received sufentanil.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2897806     DOI: 10.1111/j.1365-2044.1988.tb08970.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  9 in total

1.  Intranasal opiates: old route for new drugs.

Authors:  F E Ralley
Journal:  Can J Anaesth       Date:  1989-09       Impact factor: 5.063

2.  Anesthesia for the 21st century.

Authors:  T H Stanley
Journal:  Proc (Bayl Univ Med Cent)       Date:  2000-01

Review 3.  Adult sedation: oral, rectal, IM, IV.

Authors:  J A Giovannitti; L D Trapp
Journal:  Anesth Prog       Date:  1991 Jul-Oct

4.  Plasma sufentanil concentration after intranasal administration to paediatric outpatients.

Authors:  G Haynes; N H Brahen; H F Hill
Journal:  Can J Anaesth       Date:  1993-03       Impact factor: 5.063

Review 5.  Recent advances in the pharmacological management of pain.

Authors:  Josée Guindon; Jean-Sébastien Walczak; Pierre Beaulieu
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Pharmacokinetics of sufentanil in normal children.

Authors:  J Guay; P Gaudreault; A Tang; B Goulet; F Varin
Journal:  Can J Anaesth       Date:  1992-01       Impact factor: 5.063

7.  [New modes of opioid administration.].

Authors:  H W Striebel; R Schwagmeier; N Boerger
Journal:  Schmerz       Date:  1993-09       Impact factor: 1.107

8.  [Intranasal fentanyl for breakthrough cancer pain. A pilot study.].

Authors:  H W Striebel; A Wessel; A Rieger
Journal:  Schmerz       Date:  1993-09       Impact factor: 1.107

9.  Comparison of intravenous and intranasal sufentanil absorption and sedation.

Authors:  J H Helmers; H Noorduin; A Van Peer; L Van Leeuwen; W W Zuurmond
Journal:  Can J Anaesth       Date:  1989-09       Impact factor: 5.063

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.